$6.54
3.15% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US3596161097
Symbol
FULC

Fulcrum Therapeutics Inc Stock price

$6.54
-1.36 17.22% 1M
+2.98 83.71% 6M
+1.84 39.15% YTD
-2.47 27.41% 1Y
-1.87 22.24% 3Y
-1.23 15.83% 5Y
-6.96 51.56% 10Y
-6.96 51.56% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.20 3.15%
ISIN
US3596161097
Symbol
FULC
Industry

Key metrics

Basic
Market capitalization
$342.9m
Enterprise Value
$128.8m
Net debt
positive
Cash
$214.1m
Shares outstanding
54.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
93.2%
Return on Equity
-4.0%
ROCE
-29.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-62.9m | $-82.6m
EBIT
$-64.4m | $-83.1m
Net Income
$-55.6m | $-64.5m
Free Cash Flow
$-65.2m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
-103.8% | -352.6%
EBIT
-96.4% | -319.3%
Net Income
-174.5% | -562.6%
Free Cash Flow
-416.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.9
FCF per Share
$-1.2
Short interest
13.1%
Employees
45
Rev per Employee
$1.8m
Show more

Is Fulcrum Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Fulcrum Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Fulcrum Therapeutics Inc forecast:

10x Buy
77%
2x Hold
15%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Fulcrum Therapeutics Inc forecast:

Buy
77%
Hold
15%
Sell
8%

Financial data from Fulcrum Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
43% 43%
-
- Research and Development Expense 39 39
47% 47%
-
-63 -63
104% 104%
-
- Depreciation and Amortization 1.44 1.44
24% 24%
-
EBIT (Operating Income) EBIT -64 -64
96% 96%
-
Net Profit -56 -56
175% 175%
-

In millions USD.

Don't miss a Thing! We will send you all news about Fulcrum Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fulcrum Therapeutics Inc Stock News

Neutral
GlobeNewsWire
4 days ago
CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the comp...
Neutral
GlobeNewsWire
15 days ago
― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ―
Neutral
GlobeNewsWire
15 days ago
― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ―
More Fulcrum Therapeutics Inc News

Company Profile

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Sapir
Employees 45
Founded 2015
Website www.fulcrumtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today